Conference Schedules, Acquisition Updates, Global Footprints, and Technical Updates - Analyst Notes on Forest, CR Bard, Mallinckrodt, Covidien and WellPoint

NEW YORK, May 21, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Forest Laboratories Inc. (NYSE: FRX), CR Bard Inc. (NYSE: BCR), Mallinckrodt plc (NYSE: MNK), Covidien plc (NYSE: COV) and WellPoint Inc. (NYSE: WLP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2742-100free.

--
Forest Laboratories Inc. Analyst Notes
On May 16, 2014, shares of Forest Laboratories Inc. (Forest) gained 0.75% to end the trading session at $93.28. The stock opened the day at $92.40 and fluctuated in the range of $93.46 - $92.16. A total of 2.34 million shares were traded. Over the past 12 months, the stock has returned a phenomenal 142.10%, outperforming the NYSE Composite, which gained an upside of 10.72% during the same time period. Forest develops, manufactures and sells branded forms of ethical drug products, which requires a physician's prescription. The full analyst notes on Forest are available to download free of charge at:

http://www.analystsreview.com/2742-FRX-21May2014.pdf

--
CR Bard Inc. Analyst Notes
On May 2, 2014, CR Bard Inc. (CR Bard) announced that the Company will hold an investor conference on June 2, 2014 at 4:30 p.m. EDT in New York City. The Company informed that the conference will be hosted by Timothy M. Ring, Chairman and CEO, and will include an update on Bard's product pipeline. A webcast of the investor conference will be available for access on CR Bard's website. Headquartered in Murray Hill, New Jersey, CR Bard markets and manufactures product in the fields of vascular, urology, oncology and surgical specialty products. The full analyst notes on CR Bard are available to download free of charge at:

http://www.analystsreview.com/2742-BCR-21May2014.pdf

--
Mallinckrodt plc Analyst Notes
On May 12, 2014, Mallinckrodt plc (Mallinckrodt) and Questcor Pharmaceuticals, Inc. (Questcor), jointly announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), related to the Mallinckrodt's proposed acquisition of Questcor, was terminated by the United States Federal Trade Commission on May 9, 2014. On April 7, 2014, Mallinckrodt and Questcor entered into a definitive merger agreement, pursuant to which Mallinckrodt would acquire Questcor in a cash and stock transaction. The early termination of the HSR waiting period is in accordance with one of the conditions to the proposed acquisition. Mallinckrodt informed that the proposed acquisition remains subject to other customary closing conditions, such as approval by the shareholders of Questcor and Mallinckrodt. The merger is expected to be completed in Q3 2014, once all necessary conditions are met. The full analyst notes on Mallinckrodt are available to download free of charge at:

http://www.analystsreview.com/2742-MNK-21May2014.pdf

--
Covidien plc Analyst Notes
On May 7, 2014, Covidien plc (Covidien) announced the opening of its Covidien Center of Innovation Turkey (CCI Turkey) in an effort to expand its training and research capabilities in emerging markets. Covidien stated that the new facility, which is located in Istanbul, offers clinicians in Turkey and the surrounding region training on advanced procedures and techniques using the latest technology. José E. Almeida, Chairman, President and CEO, Covidien, commented, "At Covidien we constantly challenge each other to raise the standard of care. This investment gives us a unique and valuable opportunity to extend the reach of our innovative solutions to an underserved area." CCI Turkey is Covidien's fourth training center in an emerging market, which will focus on raising awareness of various disease states and providing opportunities for clinicians to see how Covidien's solutions can help health care professionals treat these diseases. The full analyst notes on Covidien are available to download free of charge at:

http://www.analystsreview.com/2742-COV-21May2014.pdf

--
WellPoint Inc. Analyst Notes
On May 16, 2014, shares of healthcare services provider - WellPoint Inc. (WellPoint) gained 0.18%, closing the day at $105.12. During the session, the Company's shares opened at $105.04 and oscillated in the range of $104.17 - $105.73. A total of 1.73 million shares changed hands during the session. On May 13, 2014, WellPoint's stock reached a new 52-week high of $107.59. Over the past 12 months, shares of the Company have increased 35.10%, outperforming the broader market index (S&P 500), which returned 12.61% during the same time period. The full analyst notes on WellPoint are available to download free of charge at:

http://www.analystsreview.com/2742-WLP-21May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED